You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Dow
McKesson
Mallinckrodt
Boehringer Ingelheim

Last Updated: March 28, 2020

DrugPatentWatch Database Preview

Litigation Details for Eagle Pharmaceuticals, Inc. v. Hospira, Inc. (D. Del. 2018)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Eagle Pharmaceuticals, Inc. v. Hospira, Inc. (D. Del. 2018)

Docket   Start Trial Date Filed 2018-07-19
Court District Court, D. Delaware Date Terminated
Cause 35:271 Patent Infringement Assigned To
Jury Demand Plaintiff Referred To
Parties CEPHALON, INC.; EAGLE PHARMACEUTICALS, INC.; HOSPIRA, INC.; TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Patents 10,010,533; 9,000,021; 9,034,908; 9,572,887; 9,579,384; 9,597,397; 9,597,398; 9,597,399
Attorneys Adam D. Harber; Arthur G. Connolly , III; Ben V. Picozzi; Daniel G. Brown; David I. Berl; Elise M. Baumgarten; John W. Shaw; Karen Elizabeth Keller; Kenneth G. Schuler; Marc N. Zubick; Mary I. Akhimien; Michelle L. Ernst; Nathan Roger Hoeschen; Ryan Patrick Newell; Shaun P. Mahaffy
Firms Connolly Gallagher LLP; Shaw Keller LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Eagle Pharmaceuticals, Inc. v. Hospira, Inc.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Eagle Pharmaceuticals, Inc. v. Hospira, Inc. (D. Del. 2018)

Date Filed Document No. Description Snippet Link To Document
2019-12-16 35 Opinion - Memorandum Opinion 1 U.S. Patent Nos. 10,010,533 (the "#533 patent"), 9,034,908 (the "#908 patent"),…quot;#568 patent"), 9,597,397 (the "#397 patent"), 9,597,398 (the "#398 patent")…#399 patent"), 9,000,021 (the "#021 patent"), and 9,579,384 (the ยท"#384 patent"… The ninth asserted patent, U.S. Patent No. 9,572,887 (the "#887 patent"), requires a "…quot;). to these patents as the "PG patents." In Counts II through IX and XI through XVIII of External link to document
2019-12-18 37 Opinion - Memorandum Opinion 1 U.S. Patent Nos. 10,010,533 (the "#533 patent"), 9,034,908 (the "#908 patent"),…quot;#568 patent"), 9,597,397 (the "#397 patent"), 9,597,398 (the "#398 patent")…#399 patent"), 9,000,021 (the "#021 patent"), and 9,579,384 (the "#384 patent"… The ninth asserted patent, U.S. Patent No. 9,572,887 (the "#887 patent"), requires a &…quot;). to these patents as the "PG patents." In Counts II through IX and XI through XVIII External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
McKesson
Harvard Business School
Merck
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.